Apoptosis of undifferentiated progenitors and granule cell precursors in the postnatal human cerebellar cortex correlates with expression of BCL-2, ICE, and CPP32 proteins.
Naturally occurring apoptotic cells have been demonstrated in the postnatal cerebellum of rodents (Wood et al. [1993] Neuron 11:621-632; Krueger et al. [1995] J. Neurosci. 15:3366-3374). The nature of these cells differs among species: they are considered to be granule cells in mouse and astrocytes in rat. We labeled proliferating and apoptotic cells in the postnatal human cerebellar cortex by using antibodies against the Ki-67/proliferating cell nuclear antigen and the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling method for fragmented DNA. We also immunocytochemically detected some proteins encoded by genes modulating apoptosis and specific markers of neuronal/glial differentiation. Proliferating cells were observed from birth to 4 months, representing 31-35% of cells within the external granular layer (EGL). Apoptotic cells were detected during the first 3 months and corresponded to 5-7% of EGL cells. Much lower percentages were calculated in other cortical layers and white matter. The balance between proliferation and apoptosis was quantitatively favorable to the latter during the first postnatal week. Expression of BCL-2, CPP32, and interleukin-1beta-converting enzyme (ICE) proteins was spatially and developmentally regulated in parallel with apoptosis. Apoptotic cells were often CPP32/ICE immunoreactive but negative for BCL-2. Some apoptotic cells were positive for vimentin and, less frequently, for alpha-internexin or type-III beta tubulin, but never expressed the glial fibrillary acidic protein. This study demonstrates that apoptosis is a significant phenomenon in early postnatal development of human cerebellar cortex and shares some of the regulatory mechanisms described in other vertebrates.
Lossi
L
L
Dipartimento di Morfofisiologia Veterinaria, Università degli Studi di Torino, Italy.
Zagzag
D
D
Greco
M A
MA
Merighi
A
A
D000906:Antibodies; D017209:Apoptosis / Q000502:physiology*; D015415:Biomarkers; D053148:Caspase 3; D020169:Caspases / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D002455:Cell Division / Q000502:physiology; D002525:Cerebellar Cortex / Q000737:chemistry / Q000166:cytology* / Q000201:enzymology; D003546:Cysteine Endopeptidases / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D004792:Enzyme Precursors / Q000032:analysis / Q000096:biosynthesis / Q000276:immunology; D005333:Fetus / Q000737:chemistry / Q000166:cytology / Q000201:enzymology; D006801:Humans; D020287:In Situ Nick-End Labeling; D009457:Neuroglia / Q000737:chemistry / Q000166:cytology / Q000201:enzymology; D009474:Neurons / Q000737:chemistry / Q000166:cytology / Q000201:enzymology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D013234:Stem Cells / Q000737:chemistry / Q000166:cytology* / Q000201:enzymology
D000906:Antibodies; D015415:Biomarkers; D004792:Enzyme Precursors; D019253:Proto-Oncogene Proteins c-bcl-2; C505407:CASP3 protein, human; C505409:Casp3 protein, mouse; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases; D003546:Cysteine Endopeptidases